An METTL3 inhibitor, UZH1a, was identified by the Caflisch group and has shown high nanomolar potency and good selectivity and cellular activity where in vitro demonstrated a reduction exclusively in the m6A/A ratio within acute myeloid leukemia, osteosarcoma, and kidney cancer cells. The gene discussed is METTL3; the disease is acute myeloid leukemia.